EU regulators accept Novartis’ triple asthma comboEuropean regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments Share XEU regulators accept Novartis’ triple asthma combohttps://pharmaphorum.com/news/eu-regulators-accept-novartis-triple-asthma-combo/
ICER posts damning report on Sarepta’s Duchenne drug Exondys 51Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of Share XICER posts damning report on Sarepta’s Duchenne drug Exondys 51https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/
NHS England improves offer to Vertex over CF drugsNHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to Share XNHS England improves offer to Vertex over CF drugshttps://pharmaphorum.com/news/nhs-england-improves-offer-to-vertex-over-cf-drugs/
Daiichi Sankyo in talks over OTC unit sale – reportsDaiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to Share XDaiichi Sankyo in talks over OTC unit sale – reportshttps://pharmaphorum.com/news/daiichi-sankyo-in-talks-over-otc-unit-sale-reports/
Novartis shows off pipeline – including 25 potential blockbustersNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XNovartis shows off pipeline – including 25 potential blockbustershttps://pharmaphorum.com/news/novartis-shows-off-pipeline-including-25-potential-blockbusters/
Santhera licenses LHON drug to Chiesi for €93mSanthera has announced it is licensing its LHON drug Raxone (idebenone) to Chiesi Group for an upfront payment Share XSanthera licenses LHON drug to Chiesi for €93mhttps://pharmaphorum.com/news/santhera-licenses-lhon-drug-chiesi/
Digital pharmacy MYRX365 buys RealTime ClinicMYRX365, a technology-based pharmacy company, has bought RealTime Clinic to gain access to its set of digital patient Share XDigital pharmacy MYRX365 buys RealTime Clinichttps://pharmaphorum.com/news/digital-pharmacy-myrx365-buys-realtime-clinic/
J&J’s Invokana closes on diabetic kidney disease approvalThe US FDA has granted a priority review to Johnson & Johnson’s Invokana in diabetic kidney disease, signposting Share XJ&J’s Invokana closes on diabetic kidney disease approvalhttps://pharmaphorum.com/news/jjs-invokana-closes-on-diabetic-kidney-disease-approval/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
Amgen offers $167m for drug discovery biotech NuevolutionAmgen has agreed to buy Swedish biotech Nuevolution for around $167 million to boost its drug pipeline after Share XAmgen offers $167m for drug discovery biotech Nuevolutionhttps://pharmaphorum.com/news/amgen-offers-167m-for-drug-discovery-biotech-nuevolution/
AI system beats radiologists at predicting lung cancer riskA deep learning AI system was able to detect malignant lung nodules better than radiologists in a new Share XAI system beats radiologists at predicting lung cancer riskhttps://pharmaphorum.com/news/ai-system-beats-radiologists-at-predicting-lung-cancer-risk/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
UDG Healthcare acquires Putnam Associates and Incisive HealthUDG Healthcare has boosted its Ashfield Communications and Advisory business with a brace of deals, acquiring Putnam Associates Share XUDG Healthcare acquires Putnam Associates and Incisive Healthhttps://pharmaphorum.com/news/udg-healthcare-putnam-incisive-health/
Verily signs up four big pharmas to its clinical trials platformVerily, the life sciences company owned by Google parent Alphabet, has teamed up with Novartis, Sanofi, Otsuka, and Share XVerily signs up four big pharmas to its clinical trials platformhttps://pharmaphorum.com/news/verily-signs-up-four-big-pharmas-to-its-clinical-trials-platform/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
UK’s LifeArc charity nets $1.3 billion Keytruda windfallThe UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion Share XUK’s LifeArc charity nets $1.3 billion Keytruda windfallhttps://pharmaphorum.com/news/uks-lifearc-charity-nets-1-3-billion-keytruda-windfall/
Amryt to expand rare disease portfolio with $311m Aegerion mergerRare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Share XAmryt to expand rare disease portfolio with $311m Aegerion mergerhttps://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/
2 weeks until SMi’s Pharma Microbiology West Coast Conference nearly sold out Share X2 weeks until SMi’s Pharma Microbiology West Coast Conference nearly sold outhttps://pharmaphorum.com/partner-content/2-weeks-until-smis-pharma-microbiology-west-coast-conference-nearly-sold-out/
Mapping Digital KOLs Share XMapping Digital KOLshttps://pharmaphorum.com/partner-content/mapping-digital-kols/
Registration is now open for the inaugural Wearable Injectors Conference 2019 Share XRegistration is now open for the inaugural Wearable Injectors Conference 2019https://pharmaphorum.com/partner-content/registration-is-now-open-for-the-inaugural-wearable-injectors-conference-2019/
Cleanroom industry experts join the Pharma Cleanroom Technology Conference in October Share XCleanroom industry experts join the Pharma Cleanroom Technology Conference in Octoberhttps://pharmaphorum.com/partner-content/cleanroom-industry-experts-join-the-pharma-cleanroom-technology-conference-in-october/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
